BACKGROUND AND PURPOSE: The significance of early ischemic changes (EICs) on computed tomography (CT) to triage patients for thrombolysis has been controversial. The Alberta Stroke Program Early CT Score (ASPECTS) semiquantitatively assesses EICs within the middle cerebral artery territory using a10-point grading system. We hypothesized that dichotomized ASPECTS predicts response to intravenous thrombolysis and incidence of secondary hemorrhage within 6 hours of stroke onset. METHODS:Data from the European-Australian Acute Stroke Study (ECASS) II study were used in which 800 patients were randomized to recombinant tissue plasminogen activator (rt-PA) or placebo within 6 hours of symptom onset. We retrospectively assessed all baseline CT scans, dichotomized ASPECTS at < or =7 and >7, defined favorable outcome as modified Rankin Scale score 0 to 2 after 90 days, and secondary hemorrhage as parenchymal hematoma 1 (PH1) or PH2. We performed a multivariable logistic regression analysis and assessed for an interaction between rt-PA treatment and baseline ASPECTS score. RESULTS: We scored ASPECTS >7 in 557 and < or =7 in 231 patients. There was no treatment-by-ASPECTS interaction with dichotomized ASPECTS (P=0.3). This also applied for the 0- to 3-hour and 3- to 6-hour cohorts. However, a treatment-by-ASPECTS effect modification was seen in predicting PH (0.043 for the interaction term), indicating a much higher likelihood of thrombolytic-related parenchymal hemorrhage in those with ASPECTS < or =7. CONCLUSIONS: In ECASS II, the effect of rt-PA on functional outcome is not influenced by baseline ASPECTS. Patients with low ASPECTS have a substantially increased risk of thrombolytic-related PH.
RCT Entities:
BACKGROUND AND PURPOSE: The significance of early ischemic changes (EICs) on computed tomography (CT) to triage patients for thrombolysis has been controversial. The Alberta Stroke Program Early CT Score (ASPECTS) semiquantitatively assesses EICs within the middle cerebral artery territory using a10-point grading system. We hypothesized that dichotomized ASPECTS predicts response to intravenous thrombolysis and incidence of secondary hemorrhage within 6 hours of stroke onset. METHODS: Data from the European-Australian Acute Stroke Study (ECASS) II study were used in which 800 patients were randomized to recombinant tissue plasminogen activator (rt-PA) or placebo within 6 hours of symptom onset. We retrospectively assessed all baseline CT scans, dichotomized ASPECTS at < or =7 and >7, defined favorable outcome as modified Rankin Scale score 0 to 2 after 90 days, and secondary hemorrhage as parenchymal hematoma 1 (PH1) or PH2. We performed a multivariable logistic regression analysis and assessed for an interaction between rt-PA treatment and baseline ASPECTS score. RESULTS: We scored ASPECTS >7 in 557 and < or =7 in 231 patients. There was no treatment-by-ASPECTS interaction with dichotomized ASPECTS (P=0.3). This also applied for the 0- to 3-hour and 3- to 6-hour cohorts. However, a treatment-by-ASPECTS effect modification was seen in predicting PH (0.043 for the interaction term), indicating a much higher likelihood of thrombolytic-related parenchymal hemorrhage in those with ASPECTS < or =7. CONCLUSIONS: In ECASS II, the effect of rt-PA on functional outcome is not influenced by baseline ASPECTS. Patients with low ASPECTS have a substantially increased risk of thrombolytic-related PH.
Authors: Wolfgang G Kunz; Wieland H Sommer; Christopher Höhne; Matthias P Fabritius; Felix Schuler; Franziska Dorn; Ahmed E Othman; Felix G Meinel; Louisa von Baumgarten; Maximilian F Reiser; Birgit Ertl-Wagner; Kolja M Thierfelder Journal: J Cereb Blood Flow Metab Date: 2017-01-13 Impact factor: 6.200
Authors: S Dehkharghani; R Bammer; M Straka; L S Albin; O Kass-Hout; J W Allen; S Rangaraju; D Qiu; M J Winningham; F Nahab Journal: AJNR Am J Neuroradiol Date: 2015-05-21 Impact factor: 3.825
Authors: David M Kent; Robin Ruthazer; Carole Decker; Philip G Jones; Jeffrey L Saver; Erich Bluhmki; John A Spertus Journal: Neurology Date: 2015-08-19 Impact factor: 9.910
Authors: Nika Guberina; U Dietrich; A Radbruch; J Goebel; C Deuschl; A Ringelstein; M Köhrmann; C Kleinschnitz; M Forsting; C Mönninghoff Journal: Neuroradiology Date: 2018-07-31 Impact factor: 2.804
Authors: Michael D Hill; Andrew M Demchuk; Mayank Goyal; Tudor G Jovin; Lydia D Foster; Thomas A Tomsick; Rüdiger von Kummer; Sharon D Yeatts; Yuko Y Palesch; Joseph P Broderick Journal: Stroke Date: 2013-12-12 Impact factor: 7.914
Authors: David S Liebeskind; Reza Jahan; Raul G Nogueira; Tudor G Jovin; Helmi L Lutsep; Jeffrey L Saver Journal: Stroke Date: 2014-02-13 Impact factor: 7.914